Search | IOVS | ARVO Journals

Showing 1 – 20 of 23

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Cornea December 2016

Identification of Novel Endogenous Anti(lymph)angiogenic Factors in the Aqueous Humor

PDF

Felix Bock; Jasmine Onderka; Gabriele Braun; Ann-Charlott Schneider; Deniz Hos; Yanlong Bi; Björn O. Bachmann; Claus Cursiefen
TAGS: angiogenesis factor, aqueous humor, blood alcohol concentration, cornea, lymph, mice, endothelial cells, angiogenesis, lymphatic vessels, sutures
Invest. Ophthalmol. Vis. Sci.. 2016; 57(15):6554-6560. https://doi.org/10.1167/iovs.15-18526

ARVO Annual Meeting Abstract June 2013

Candidate regulatory lysyl oxidase-like 1 (LOXL1) variants in pseudoexfoliation syndrome/glaucoma are associated with differential LOXL1 expression

Matthias Zenkel; Francesca Pasutto; Jasmine Onderka; Anita Krysta; Angelika Moessner; Friedrich Kruse; Ursula Schlotzer-Schrehardt

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6243.

ARVO Annual Meeting Abstract March 2012

Reduced Hem- And Lymphangiogenesis Into A Fishscale-derived Collagen Scaffold Used As Biological Artificial Cornea (BioCornea)

Deniz Hos; Felix Bock; Birgit Regenfuss; Jasmine Onderka; Chien C. Lin; Horng J. Lai; Claus Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6040.

ARVO Annual Meeting Abstract March 2012

TRAIL Influences Human Lymphatic Microvascular Endothelial Cell (HMVECs) Proliferation and Lymphangiogenesis

Birgit Regenfuss; Deniz Hos; Felix Bock; Jasmine Onderka; Sharmila Masli; Claus Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2398.

Cornea July 2011

Blockade of Insulin Receptor Substrate-1 Inhibits Corneal Lymphangiogenesis

PDF

Deniz Hos; Birgit Regenfuss; Felix Bock; Jasmine Onderka; Claus Cursiefen
TAGS: cornea, irs1 protein, human, lymphangiogenesis, macrophages, insulin receptor, lymphatic vessels, vascular endothelial growth factor a, growth factor, endothelial cells, vascular endothelial growth factor c
Invest. Ophthalmol. Vis. Sci.. 2011; 52(8):5778-5785. https://doi.org/10.1167/iovs.10-6816

ARVO Annual Meeting Abstract April 2011

Molecular Profiling Of The Naïve Cornea In Different Mouse Strains

Birgit Regenfuss; Deniz Hos; Felix Bock; Jasmine Onderka; Claus Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6389.

ARVO Annual Meeting Abstract April 2010

Corticosteroids Inhibit Inflammatory Corneal Lymphangigenesis in vivo, but Display Proangiogenic Properties in vitro

D. Hos; F. Bock; D. R. Saban; B. Regenfuss; J. Onderka; S. Masli; R. Dana; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5695.

Cornea May 2009

Safety Profile of Topical VEGF Neutralization at the Cornea

PDF

Felix Bock; Jasmine Onderka; Carmen Rummelt; Tina Dietrich; Björn Bachmann; Friedrich E. Kruse; Ursula Schlötzer-Schrehardt; Claus Cursiefen
TAGS: antibodies, bevacizumab, cornea, eyedrops, neutralization, safety, vascular endothelial growth factor a, anti-vascular endothelial growth factor therapy, epithelium, wound healing
Invest. Ophthalmol. Vis. Sci.. 2009; 50(5):2095-2102. https://doi.org/10.1167/iovs.07-1129

ARVO Annual Meeting Abstract April 2009

Topical Antisense Oligonucleotide Eye Drops Against Insulin Receptor Substrate 1 Inhibit Inflammatory Corneal Lymphangiogenesis

D. Hos; J. Onderka; F. Bock; B. Regenfuß; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4947.

ARVO Annual Meeting Abstract April 2009

Heterogeneity of Inflammatory Corneal Lymphangiogenesis in Different Inbred Mouse Strains

B. Regenfuss; F. Bock; J. Onderka; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4948.

ARVO Annual Meeting Abstract April 2009

Three-Dimensional Imaging of Lymphatic Vessels in the Inflamed Cornea by ex-vivo Two-Photon Microscopy

F. Bock; P. Steven; J. Onderka; B. Regenfuß; G. Hüttmann; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4957.

ARVO Annual Meeting Abstract May 2008

Integrin Alpha 5 Inhibition Improves Corneal Graft Survival in a Murine Model of High-Risk Keratoplasty

T. Dietrich; J. Onderka; F. Bock; D. Hos; G. Zahn; R. Stragies; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5761.

ARVO Annual Meeting Abstract May 2008

Lymphatic Vessels Determine the High-Risk Status of Vascularized Recipient Corneas

F. Bock; D. Hos; T. Dietrich; J. Onderka; B. Bachmann; F. E. Kruse; S. J. Wiegand; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1484.

ARVO Annual Meeting Abstract May 2008

Pegaptanib (Macugen) and Ranibizumab (Lucentis) Eye Drops Inhibit Inflammatory Corneal Neovascularization

A. Parthasarathy; F. Bock; J. Onderka; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):3746.

Cornea May 2008

Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation

PDF

Deniz Hos; Felix Bock; Tina Dietrich; Jasmine Onderka; Friedrich E. Kruse; Karl-Heinz Thierauch; Claus Cursiefen
TAGS: cornea, graft survival, keratoplasty, protein-tyrosine kinase inhibitor, vascular endothelial growth factor receptors, kinase inhibitors, tyrosine, angiogenesis, lymph, lymphangiogenesis
Invest. Ophthalmol. Vis. Sci.. 2008; 49(5):1836-1842. https://doi.org/10.1167/iovs.07-1314

Cornea June 2007

Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis

PDF

Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E. Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
TAGS: bevacizumab, corneal neovascularization, lymphangiogenesis, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2007; 48(6):2545-2552. https://doi.org/10.1167/iovs.06-0570

ARVO Annual Meeting Abstract May 2007

Effect of Integrin Alpha 5 Inhibition on Lymphangiogenesis and Recruitment of CD11b-Positive Macrophages in a Murine Model of High-Risk Keratoplasty

T. Dietrich; J. Onderka; F. Bock; D. Hos; G. Zahn; R. Stragies; F. E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):181.

ARVO Annual Meeting Abstract May 2007

Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation

D. Hos; F. Bock; T. Dietrich; J. Onderka; F. E. Kruse; K. H. Thierauch; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1696.

ARVO Annual Meeting Abstract May 2007

Thrombospondin 1 Is an Endogenous Inhibitor of Inflammatory Lymphangiogenesis and Maintains Corneal Lymphangiogenic Privilege

C. Cursiefen; F. Bock; J. Onderka; F. E. Kruse; K. Maruyama; J. Lawler; R. Dana; S. Masli

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):3196.

ARVO Annual Meeting Abstract May 2007

Aqueous Humour Displays Antilymphangiogenic Effects

F. Bock; J. Onderka; T. Dietrich; B. Bachmann; F. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):3200.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Identification of Novel Endogenous Anti(lymph)angiogenic Factors in the Aqueous Humor

Candidate regulatory lysyl oxidase-like 1 (LOXL1) variants in pseudoexfoliation syndrome/glaucoma are associated with differential LOXL1 expression

Reduced Hem- And Lymphangiogenesis Into A Fishscale-derived Collagen Scaffold Used As Biological Artificial Cornea (BioCornea)

TRAIL Influences Human Lymphatic Microvascular Endothelial Cell (HMVECs) Proliferation and Lymphangiogenesis

Blockade of Insulin Receptor Substrate-1 Inhibits Corneal Lymphangiogenesis

Molecular Profiling Of The Naïve Cornea In Different Mouse Strains

Corticosteroids Inhibit Inflammatory Corneal Lymphangigenesis in vivo, but Display Proangiogenic Properties in vitro

Safety Profile of Topical VEGF Neutralization at the Cornea

Topical Antisense Oligonucleotide Eye Drops Against Insulin Receptor Substrate 1 Inhibit Inflammatory Corneal Lymphangiogenesis

Heterogeneity of Inflammatory Corneal Lymphangiogenesis in Different Inbred Mouse Strains

Three-Dimensional Imaging of Lymphatic Vessels in the Inflamed Cornea by ex-vivo Two-Photon Microscopy

Integrin Alpha 5 Inhibition Improves Corneal Graft Survival in a Murine Model of High-Risk Keratoplasty

Lymphatic Vessels Determine the High-Risk Status of Vascularized Recipient Corneas

Pegaptanib (Macugen) and Ranibizumab (Lucentis) Eye Drops Inhibit Inflammatory Corneal Neovascularization

Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation

Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis

Effect of Integrin Alpha 5 Inhibition on Lymphangiogenesis and Recruitment of CD11b-Positive Macrophages in a Murine Model of High-Risk Keratoplasty

Tyrosine Kinase Inhibitors Block Inflammatory Corneal Hem- and Lymphangiogenesis and Improve Graft Survival After Corneal Transplantation

Thrombospondin 1 Is an Endogenous Inhibitor of Inflammatory Lymphangiogenesis and Maintains Corneal Lymphangiogenic Privilege

Aqueous Humour Displays Antilymphangiogenic Effects

To View More...

You must be signed into an individual account to use this feature.